Neuroaxial Blokade and Blood Pressure

NCT ID: NCT00435422

Last Updated: 2010-03-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The effect of individualized fluid optimization during neuroaxial blockade has not been evaluated. The investigators evaluated if if Stroke decrease 15 min after activation of neuroaxial blockade and whether SV could be optimized to pre activation values.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate SV maximization with aid of the LiDCO system which is a minimal invasive technique only requiring a venous and arterial line. We thereby attempt to cover the specific individual fluid deficit induced by neuroaxial blockade.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypovolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stroke volume optimization

Stroke volume optimization

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Neuroaxial blockade (thoracic)

Exclusion Criteria

* Weight below 40 kg
* Lithium therapy
* Type I diabetes or type II requiring insulin
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rigshospitalet

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Morten Bundgaard-Nielsen, MD

Role: PRINCIPAL_INVESTIGATOR

Section of surgical pathophysiology

Morten Bundgaard-Nielsen, MD

Role: PRINCIPAL_INVESTIGATOR

unafiliated

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Morten Bundgaard-Nielsen, MD

Role: CONTACT

0045 35 45 09 55

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Morten Bundgaard-Nielsen, MD

Role: primary

Hans-Jørgen B Frederiksen, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Neuroaxial blokade and BP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Preventive Sodium Lactate and Traumatic Brain Injury
NCT00995683 COMPLETED PHASE2/PHASE3
Whole Body Cooling Using Phase Changing Material
NCT01138176 UNKNOWN PHASE1/PHASE2